Sousa-Pinto B.Louis R.Anto J.M.Amaral R.Sá-Sousa A.Czarlewski W.Brussino L.Canonica G.W.Chaves Loureiro C.Cruz A.A.Gemicioglu B.Haahtela T.Kupczyk M.Kvedariene V.Larenas-Linnemann D.E.Okamoto Y.Ollert M.Pfaar O.Pham-Thi N.Puggioni F.Regateiro F.S.Romantowski J.Sastre J.Scichilone N.Taborda-Barata L.Ventura M.T.Agache I.Bedbrook A.Becker S.Bergmann K.C.Bosnic-Anticevich S.Bonini M.Boulet L.-P.Brusselle G.Buhl R.Cecchi L.Charpin D.de Blay F.Del Giacco S.Ivancevich J.C.Jutel M.Klimek L.Kraxner H.Kuna P.Laune D.Makela M.Morais-Almeida M.Nadif R.Niedoszytko M.Papadopoulos N.G.Papi A.Patella V.Pétré B.Rivero Yeverino D.Robalo Cordeiro C.Roche N.Rouadi P.W.Samolinski B.Savouré M.Shamji M.H.Sheikh A.Suppli Ulrik C.Usmani O.S.Valiulis A.Yorgancioglu A.Zuberbier T.Fonseca J.A.Costa E.M.Bousquet J.2024-07-222024-07-22202325310429http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12216Introduction: Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting β2-agonists (ICS+LABA) in users of the MASK-air® app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA. Materials and methods: We analysed complete weeks of MASK-air® data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day. Results: In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ≥80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001). Conclusions: In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control. © 2023 Sociedade Portuguesa de PneumologiaEnglishAll Open Access; Gold Open AccessArticle10.1016/j.pulmoe.2023.07.004